PROMOMED Serves as General Partner of the 2025 National Diabetology Congress
From May 27 to 30, Moscow hosted the largest scientific and practical event in the field of endocrinology—the 10th (31st) National Diabetology Congress with international participation, titled "Diabetes Mellitus – A Non-Communicable Pandemic of the 21st Century. Macro- and Microvascular Complications. Issues of Interdisciplinary Collaboration." PROMOMED Group served as the General Partner of the Congress.
The event was dedicated to two major milestones: the 100th anniversary of the Russian Association of Endocrinologists and the 100th anniversary of the Endocrinology Research Center. During the ceremonial plenary session, Petr Aleksandrovich Bely, Founder and Chairman of the Board of Directors of PROMOMED, personally congratulated and expressed his gratitude to Ivan Ivanovich Dedov—President of the Russian Association of Endocrinologists, Scientific Director of the Endocrinology Research Center, Academician of the Russian Academy of Sciences, Hero of Labor of the Russian Federation, and Chief Freelance Endocrinologist of the Ministry of Health of Russia—for his partnership in the fight against diabetes and obesity.
As part of the Congress, PROMOMED successfully held three symposia featuring leading national experts on pressing topics. The company’s vibrant and interactive booth attracted more than 3,000 participants from Russia and abroad. A “Health Room” was available at the booth, where all interested attendees could assess their metabolic health using bioimpedance and a metabolic cart.
PROMOMED’s active and impactful participation at the Congress reaffirmed the company’s leadership in developing innovative solutions for the treatment of obesity and diabetes. With a broad portfolio of medications—including Reduxin®, Reduxin® Forte, Enligria®, Welgia®, Queensenta®, and Tirzetta®—the company offers a personalized approach to tailored treatment for every patient in need.
